PolyPid (NASDAQ:PYPD) Stock Rating Upgraded by RODMAN&RENSHAW

PolyPid (NASDAQ:PYPD) was upgraded by research analysts at RODMAN&RENSHAW to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

PYPD has been the topic of several other reports. Rodman & Renshaw started coverage on PolyPid in a research report on Tuesday. They set a “buy” rating and a $13.00 price objective on the stock. Craig Hallum assumed coverage on PolyPid in a research report on Monday, November 4th. They issued a “buy” rating and a $10.00 price target for the company. Finally, HC Wainwright lowered their price objective on PolyPid from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday, December 26th.

PolyPid Stock Up 2.1 %

Shares of NASDAQ:PYPD opened at $2.98 on Tuesday. PolyPid has a one year low of $2.37 and a one year high of $7.00. The firm has a fifty day moving average price of $3.11 and a two-hundred day moving average price of $3.36. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.00 and a quick ratio of 1.00. The company has a market cap of $14.30 million, a price-to-earnings ratio of -0.38 and a beta of 1.32.

Institutional Trading of PolyPid

An institutional investor recently bought a new position in PolyPid stock. Stonepine Capital Management LLC bought a new stake in shares of PolyPid Ltd. (NASDAQ:PYPD) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 138,504 shares of the company’s stock, valued at approximately $476,000. Stonepine Capital Management LLC owned approximately 2.89% of PolyPid at the end of the most recent quarter. Institutional investors own 26.47% of the company’s stock.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.